BA
FOLD

Bridgewater Associates’s Amicus Therapeutics FOLD Stock Holding History

Bridgewater Associates’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,274
Closed -$460K – 1091
2025
Q4 		$460K Buy
+32,274
New +$317K ﹤0.01% 980

Other funds holding FOLD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Bridgewater Associates's FOLD Position: Q1 2026 in Review

Bridgewater Associates sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 32,274 shares — an estimated $460K sold.

Bridgewater Associates first reported a position in FOLD in Q4 2025 and held it in 1 quarter. The position peaked at $460K in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Bridgewater Associates reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bridgewater Associates sold 32,274 Amicus Therapeutics shares in Q1 2026, an estimated $460K.
  • Bridgewater Associates first reported a position in Amicus Therapeutics in Q4 2025 and held it in 1 quarter.
  • Bridgewater Associates's Amicus Therapeutics position peaked at $460K in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.